# An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo

Source: https://onco.cc/trials/nct04076059/  
OnCo record `nct04076059` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Enzalutamide in prostate cancer, run by Astellas (Beijing) Pharmaceutical R&D Co., Ltd., active and no longer recruiting.

## Summary

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) is a phase 3 interventional study registered as NCT04076059 by Astellas (Beijing) Pharmaceutical R&D Co., Ltd., with 180 participants enrolled, started 2019-09-11 and due to reach its primary completion in 2022-11-18. Interventions recorded: Enzalutamide, Placebo, Androgen deprivation therapy (ADT). Conditions listed: Metastatic Hormone Sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04076059
- Phase: 3
- Setting: China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
- Sponsor: Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT04076059: https://clinicaltrials.gov/study/NCT04076059

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Enzalutamide](https://onco.cc/drugs/enzalutamide/)
- companies: [Astellas](https://onco.cc/companies/astellas/)

---
JSON: https://onco.cc/api/v1/entities/nct04076059.json